These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 8435987)

  • 1. Hypersecretion of truncated glucagon-like peptide-1 and gastric inhibitory polypeptide in obese patients.
    Fukase N; Igarashi M; Takahashi H; Manaka H; Yamatani K; Daimon M; Tominaga M; Sasaki H
    Diabet Med; 1993; 10(1):44-9. PubMed ID: 8435987
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Response of truncated glucagon-like peptide-1 and gastric inhibitory polypeptide to glucose ingestion in non-insulin dependent diabetes mellitus. Effect of sulfonylurea therapy.
    Fukase N; Manaka H; Sugiyama K; Takahashi H; Igarashi M; Daimon M; Yamatani K; Tominaga M; Sasaki H
    Acta Diabetol; 1995 Oct; 32(3):165-9. PubMed ID: 8590785
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus.
    Vilsbøll T; Krarup T; Sonne J; Madsbad S; Vølund A; Juul AG; Holst JJ
    J Clin Endocrinol Metab; 2003 Jun; 88(6):2706-13. PubMed ID: 12788877
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differences in glucagon-like peptide-1 and GIP responses following sucrose ingestion.
    Fukase N; Takahashi H; Manaka H; Igarashi M; Yamatani K; Daimon M; Sugiyama K; Tominaga M; Sasaki H
    Diabetes Res Clin Pract; 1992 Mar; 15(3):187-95. PubMed ID: 1576919
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus.
    Nauck MA; Heimesaat MM; Orskov C; Holst JJ; Ebert R; Creutzfeldt W
    J Clin Invest; 1993 Jan; 91(1):301-7. PubMed ID: 8423228
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gut incretin hormones in identical twins discordant for non-insulin-dependent diabetes mellitus (NIDDM)--evidence for decreased glucagon-like peptide 1 secretion during oral glucose ingestion in NIDDM twins.
    Vaag AA; Holst JJ; Vølund A; Beck-Nielsen HB
    Eur J Endocrinol; 1996 Oct; 135(4):425-32. PubMed ID: 8921824
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Normal secretion and action of the gut incretin hormones glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in young men with low birth weight.
    Schou JH; Pilgaard K; Vilsbøll T; Jensen CB; Deacon CF; Holst JJ; Vølund A; Madsbad S; Vaag AA
    J Clin Endocrinol Metab; 2005 Aug; 90(8):4912-9. PubMed ID: 15899957
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exaggerated release and preserved insulinotropic action of glucagon-like peptide-1 underlie insulin hypersecretion in glucose-tolerant individuals after Roux-en-Y gastric bypass.
    Dirksen C; Bojsen-Møller KN; Jørgensen NB; Jacobsen SH; Kristiansen VB; Naver LS; Hansen DL; Worm D; Holst JJ; Madsbad S
    Diabetologia; 2013 Dec; 56(12):2679-87. PubMed ID: 24048673
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Degradation and glycemic effects of His(7)-glucitol glucagon-like peptide-1(7-36)amide in obese diabetic ob/ob mice.
    O'Harte FP; Mooney MH; Kelly CM; McKillop AM; Flatt PR
    Regul Pept; 2001 Jan; 96(3):95-104. PubMed ID: 11111014
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of postprandial releases of insulin and incretin hormones in meal-induced satiety--effect of obesity and weight reduction.
    Verdich C; Toubro S; Buemann B; Lysgård Madsen J; Juul Holst J; Astrup A
    Int J Obes Relat Metab Disord; 2001 Aug; 25(8):1206-14. PubMed ID: 11477506
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral glutamine increases circulating glucagon-like peptide 1, glucagon, and insulin concentrations in lean, obese, and type 2 diabetic subjects.
    Greenfield JR; Farooqi IS; Keogh JM; Henning E; Habib AM; Blackwood A; Reimann F; Holst JJ; Gribble FM
    Am J Clin Nutr; 2009 Jan; 89(1):106-113. PubMed ID: 19056578
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of sub-chronic exposure to naturally occurring N-terminally truncated metabolites of glucose-dependent insulinotrophic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), GIP(3-42) and GLP-1(9-36)amide, on insulin secretion and glucose homeostasis in ob/ob mice.
    Parker JC; Lavery KS; Irwin N; Green BD; Greer B; Harriott P; O'Harte FP; Gault VA; Flatt PR
    J Endocrinol; 2006 Oct; 191(1):93-100. PubMed ID: 17065392
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gastric inhibitory polypeptide analogues: do they have a therapeutic role in diabetes mellitus similar to that of glucagon-like Peptide-1?
    Holst JJ
    BioDrugs; 2002; 16(3):175-81. PubMed ID: 12102645
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Release of glucagon-like peptide 1 (GLP-1 [7-36 amide]), gastric inhibitory polypeptide (GIP) and insulin in response to oral glucose after upper and lower intestinal resections.
    Nauck MA; Siemsglüss J; Orskov C; Holst JJ
    Z Gastroenterol; 1996 Mar; 34(3):159-66. PubMed ID: 8650968
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of carbohydrate-mediated glucagon-like peptide-1 (7-36)amide secretion by circulating non-esterified fatty acids.
    Ranganath L; Norris F; Morgan L; Wright J; Marks V
    Clin Sci (Lond); 1999 Apr; 96(4):335-42. PubMed ID: 10087239
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human duodenal enteroendocrine cells: source of both incretin peptides, GLP-1 and GIP.
    Theodorakis MJ; Carlson O; Michopoulos S; Doyle ME; Juhaszova M; Petraki K; Egan JM
    Am J Physiol Endocrinol Metab; 2006 Mar; 290(3):E550-9. PubMed ID: 16219666
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Secretion of incretin hormones and the insulinotropic effect of gastric inhibitory polypeptide in women with a history of gestational diabetes.
    Meier JJ; Gallwitz B; Askenas M; Vollmer K; Deacon CF; Holst JJ; Schmidt WE; Nauck MA
    Diabetologia; 2005 Sep; 48(9):1872-81. PubMed ID: 16010522
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Secretion, degradation, and elimination of glucagon-like peptide 1 and gastric inhibitory polypeptide in patients with chronic renal insufficiency and healthy control subjects.
    Meier JJ; Nauck MA; Kranz D; Holst JJ; Deacon CF; Gaeckler D; Schmidt WE; Gallwitz B
    Diabetes; 2004 Mar; 53(3):654-62. PubMed ID: 14988249
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The pathophysiology of diabetes involves a defective amplification of the late-phase insulin response to glucose by glucose-dependent insulinotropic polypeptide-regardless of etiology and phenotype.
    Vilsbøll T; Knop FK; Krarup T; Johansen A; Madsbad S; Larsen S; Hansen T; Pedersen O; Holst JJ
    J Clin Endocrinol Metab; 2003 Oct; 88(10):4897-903. PubMed ID: 14557471
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Orlistat augments postprandial increases in glucagon-like peptide 1 in obese type 2 diabetic patients.
    Damci T; Yalin S; Balci H; Osar Z; Korugan U; Ozyazar M; Ilkova H
    Diabetes Care; 2004 May; 27(5):1077-80. PubMed ID: 15111524
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.